Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
about
A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primatesSublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge.Invariant NKT cells: regulation and function during viral infection.Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant.Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvantsIntranasal Vaccination Affords Localization and Persistence of Antigen-Specific CD8⁺ T Lymphocytes in the Female Reproductive Tract.Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.A Distinct Lung-Interstitium-Resident Memory CD8(+) T Cell Subset Confers Enhanced Protection to Lower Respiratory Tract InfectionIntranasal formulations: promising strategy to deliver vaccines.Eliciting Epitope-Specific CD8+ T Cell Response by Immunization with Microbial Protein Antigens Formulated with α-Galactosylceramide: Theory, Practice, and Protocols.Key role for respiratory CD103(+) dendritic cells, IFN-γ, and IL-17 in protection against Streptococcus pneumoniae infection in response to α-galactosylceramide.Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus.Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in MicThe Influence of Invariant Natural Killer T Cells on Humoral Immunity to T-Dependent and -Independent Antigens.
P2860
Q27303293-074512F1-B21D-4207-9EC3-90D4B2C236DEQ31153121-738A4379-8533-4ED1-93DD-E21A0C2C41E3Q34390484-71965F4E-CCA4-46DC-B0F9-272028B99CC3Q34625185-3412A5F3-07ED-4EF9-AF26-89A5A9216749Q34781602-8CBD31A3-3776-4F80-9DF6-9F92C721FA30Q36103115-58BE99F3-D7F1-4551-9C9D-47611BA18933Q36383130-46A3FFB9-1564-4B32-AA7A-CE1FC9169725Q36474450-5E319E7F-076D-4467-AF18-118CD2ECB1C1Q36735275-7C4BB3C6-BC9A-48B9-9A0E-934AFD785933Q36978334-D58A3383-C3A7-4B6B-96CF-783C9D92D425Q37253257-FF6DB6BD-37EE-47B2-8580-3DFBEB7AE45BQ38223050-04AD5701-7750-400B-8D78-66ADE27F8B6CQ40513167-CED7AE6E-1250-448D-A204-D6A78EA1BB1BQ42717336-BA0DD61F-ED45-4502-96E3-5F0A1505299EQ46882098-587508DE-A60A-4F67-A4B6-43CD8A4A1196Q47324477-6CD53936-CFAA-4B46-BB1E-3BC4F0FF95E4Q50531631-E0D9E455-5BCC-4128-A960-4C4A09F686A3
P2860
Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Intranasal but not intravenous ...... al killer T cells in the lung.
@ast
Intranasal but not intravenous ...... al killer T cells in the lung.
@en
type
label
Intranasal but not intravenous ...... al killer T cells in the lung.
@ast
Intranasal but not intravenous ...... al killer T cells in the lung.
@en
prefLabel
Intranasal but not intravenous ...... al killer T cells in the lung.
@ast
Intranasal but not intravenous ...... al killer T cells in the lung.
@en
P2093
P2860
P356
P1476
Intranasal but not intravenous ...... ral killer T cells in the lung
@en
P2093
Ameerah M Wishahy
Amy N Courtney
Prakash Thapa
Shailbala Singh
P2860
P304
P356
10.1002/EJI.201041359
P407
P577
2011-09-19T00:00:00Z